Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

b'Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina\xe2\x80\x99s comprehensive genomic profiling assay, TruSight\xe2\x84\xa2 Oncology 500 (TSO 500).